STAT3 gene changes and immune balance
STAT3 variants as a rheostat of immune tolerance
Researchers are working on ways to fix harmful STAT3 gene changes that can cause immune problems in people with autoimmune conditions, including forms of diabetes.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11261109 on NIH RePORTER |
What this research studies
This program brings together three teams to study how specific STAT3 gene changes tip the immune system toward autoimmunity. Teams will analyze immune cells from people with STAT3 gain-of-function changes, use animal models to see how those changes cause skin inflammation and type 1 diabetes, and apply CRISPR/Cas9 techniques to study and attempt genetic repair of STAT3 in human cells. Two scientific cores will support shared resources and collaborative experiments across projects. The work combines patient-derived samples, cutting-edge gene-editing tools, and animal studies to point toward potential therapies.
Who could benefit from this research
Good fit: Ideal candidates would include people known to have STAT3 gain-of-function mutations or patients with autoimmune/brittle diabetes interested in contributing samples or joining related clinical efforts.
Not a fit: People whose diabetes or immune problems are unrelated to STAT3 mutations may not see direct benefit from this specific work.
Why it matters
Potential benefit: If successful, this work could lead to treatments that correct STAT3 defects and reduce harmful autoimmune responses such as those seen in type 1 or brittle diabetes.
How similar studies have performed: Previous research has linked STAT3 mutations to autoimmune disease, but using CRISPR-based repair in human cells is a newer, largely preclinical approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Anderson, Mark S — University of California, San Francisco
- Study coordinator: Anderson, Mark S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.